298 related articles for article (PubMed ID: 32350708)
1. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation.
Le Cras TD; Goines J; Lakes N; Pastura P; Hammill AM; Adams DM; Boscolo E
Angiogenesis; 2020 Aug; 23(3):425-442. PubMed ID: 32350708
[TBL] [Abstract][Full Text] [Related]
2. A xenograft model for venous malformation.
Goines J; Li X; Cai Y; Mobberley-Schuman P; Metcalf M; Fishman SJ; Adams DM; Hammill AM; Boscolo E
Angiogenesis; 2018 Nov; 21(4):725-735. PubMed ID: 29786783
[TBL] [Abstract][Full Text] [Related]
3. Somatic Activating PIK3CA Mutations Cause Venous Malformation.
Limaye N; Kangas J; Mendola A; Godfraind C; Schlögel MJ; Helaers R; Eklund L; Boon LM; Vikkula M
Am J Hum Genet; 2015 Dec; 97(6):914-21. PubMed ID: 26637981
[TBL] [Abstract][Full Text] [Related]
4. Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations.
Brouillard P; Schlögel MJ; Homayun Sepehr N; Helaers R; Queisser A; Fastré E; Boutry S; Schmitz S; Clapuyt P; Hammer F; Dompmartin A; Weitz-Tuoretmaa A; Laranne J; Pasquesoone L; Vilain C; Boon LM; Vikkula M
Orphanet J Rare Dis; 2021 Jun; 16(1):267. PubMed ID: 34112235
[TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations.
Blesinger H; Kaulfuß S; Aung T; Schwoch S; Prantl L; Rößler J; Wilting J; Becker J
PLoS One; 2018; 13(7):e0200343. PubMed ID: 29985963
[TBL] [Abstract][Full Text] [Related]
7. AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation.
Boscolo E; Coma S; Luks VL; Greene AK; Klagsbrun M; Warman ML; Bischoff J
Angiogenesis; 2015 Apr; 18(2):151-62. PubMed ID: 25424831
[TBL] [Abstract][Full Text] [Related]
8. A Xenograft Model for Venous Malformation.
Goines J; Boscolo E
Methods Mol Biol; 2021; 2206():179-192. PubMed ID: 32754818
[TBL] [Abstract][Full Text] [Related]
9. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
[TBL] [Abstract][Full Text] [Related]
10. Shear stress and pathophysiological PI3K involvement in vascular malformations.
Abdelilah-Seyfried S; Ola R
J Clin Invest; 2024 May; 134(10):. PubMed ID: 38747293
[TBL] [Abstract][Full Text] [Related]
11. A PIK3CA mutation in an acquired capillary malformation.
Rosenthal J; Sibbald C; Jen M; Deardorff MA; Treat J
Pediatr Dermatol; 2020 Jan; 37(1):246-247. PubMed ID: 31830321
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutations in vascular malformations.
Castillo SD; Baselga E; Graupera M
Curr Opin Hematol; 2019 May; 26(3):170-178. PubMed ID: 30855339
[TBL] [Abstract][Full Text] [Related]
13. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.
Castillo SD; Tzouanacou E; Zaw-Thin M; Berenjeno IM; Parker VE; Chivite I; Milà-Guasch M; Pearce W; Solomon I; Angulo-Urarte A; Figueiredo AM; Dewhurst RE; Knox RG; Clark GR; Scudamore CL; Badar A; Kalber TL; Foster J; Stuckey DJ; David AL; Phillips WA; Lythgoe MF; Wilson V; Semple RK; Sebire NJ; Kinsler VA; Graupera M; Vanhaesebroeck B
Sci Transl Med; 2016 Mar; 8(332):332ra43. PubMed ID: 27030595
[TBL] [Abstract][Full Text] [Related]
14. Endothelial
Huang L; Bichsel C; Norris AL; Thorpe J; Pevsner J; Alexandrescu S; Pinto A; Zurakowski D; Kleiman RJ; Sahin M; Greene AK; Bischoff J
Arterioscler Thromb Vasc Biol; 2022 Jan; 42(1):e27-e43. PubMed ID: 34670408
[TBL] [Abstract][Full Text] [Related]
15. Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation.
Martinez-Corral I; Zhang Y; Petkova M; Ortsäter H; Sjöberg S; Castillo SD; Brouillard P; Libbrecht L; Saur D; Graupera M; Alitalo K; Boon L; Vikkula M; Mäkinen T
Nat Commun; 2020 Jun; 11(1):2869. PubMed ID: 32513927
[TBL] [Abstract][Full Text] [Related]
16. Response to sirolimus in capillary lymphatic venous malformations and associated syndromes: Impact on symptomatology, quality of life, and radiographic response.
Engel ER; Hammill A; Adams D; Phillips RJ; Jeng M; Tollefson MM; Iacobas I; Schiff D; Greenberger S; Kelly M; Frieden I; Zaghloul N; Drolet B; Geddis A; Goldenberg D; Ricci K
Pediatr Blood Cancer; 2023 Apr; 70(4):e30215. PubMed ID: 36651691
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA).
Hori Y; Hirose K; Ozeki M; Hata K; Motooka D; Tahara S; Matsui T; Kohara M; Higashihara H; Ono Y; Tanaka K; Toyosawa S; Morii E
Diagn Pathol; 2022 Jan; 17(1):19. PubMed ID: 35094709
[TBL] [Abstract][Full Text] [Related]
18. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA.
Luks VL; Kamitaki N; Vivero MP; Uller W; Rab R; Bovée JV; Rialon KL; Guevara CJ; Alomari AI; Greene AK; Fishman SJ; Kozakewich HP; Maclellan RA; Mulliken JB; Rahbar R; Spencer SA; Trenor CC; Upton J; Zurakowski D; Perkins JA; Kirsh A; Bennett JT; Dobyns WB; Kurek KC; Warman ML; McCarroll SA; Murillo R
J Pediatr; 2015 Apr; 166(4):1048-54.e1-5. PubMed ID: 25681199
[TBL] [Abstract][Full Text] [Related]
19. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
[TBL] [Abstract][Full Text] [Related]
20. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
